PMID- 35494052
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Effectiveness and Safety of Toripalimab Combination Therapies for Patients With 
      Chemo-Resistant Choriocarcinoma.
PG  - 815917
LID - 10.3389/fonc.2022.815917 [doi]
LID - 815917
AB  - Toripalimab as a novel PD-1 inhibitor has presented its promising efficacy in 
      patients who developed chemo-refractory carcinomas, whereas no study has ever 
      investigated the effectiveness of toripalimab in chemo-resistant choriocarcinoma. 
      Here we reported the effectiveness and safety data of 4 patients with 
      chemo-resistant choriocarcinoma who underwent PD-1 antibody therapy by 
      toripalimab and individualized chemotherapies. From January 2019 to August 2020, 
      4 patients with choriocarcinoma were admitted in Shengjing Hospital of China 
      Medical University. The patients' age ranged from 29 to 52 years with a median of 
      36 years. All the patients achieved CR after the combined therapy of toripalimab 
      with individualized chemotherapies according to the decreased serum beta-hcg level. 
      Two of the four patients were observed with treatment-related adverse events 
      (AEs), including one grade I skin rash and one grade I pruritus. Our cases showed 
      that toripalimab combined with chemotherapy presented a tolerable safety profile 
      and promising effectiveness in patients with chemo-resistant choriocarcinoma, 
      indicating its potential as salvage therapy for this subset of patients.
CI  - Copyright (c) 2022 Liu, Li, Qu, Zhang, Zhang and Du.
FAU - Liu, Xiaomei
AU  - Liu X
AD  - Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical 
      University, Shenyang, China.
FAU - Li, Xiuqin
AU  - Li X
AD  - Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical 
      University, Shenyang, China.
FAU - Qu, Hui
AU  - Qu H
AD  - Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical 
      University, Shenyang, China.
FAU - Zhang, Shiyue
AU  - Zhang S
AD  - Shanghai Junshi Biosciences Co, Ltd., Shanghai, China.
FAU - Zhang, Ruizhe
AU  - Zhang R
AD  - Shanghai Junshi Biosciences Co, Ltd., Shanghai, China.
FAU - Du, Zhenhua
AU  - Du Z
AD  - Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical 
      University, Shenyang, China.
LA  - eng
PT  - Journal Article
DEP - 20220414
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9047865
OTO - NOTNLM
OT  - PD-1 checkpoint inhibitors
OT  - chemo-resistant
OT  - choriocarcinoma
OT  - effectiveness and safety
OT  - toripalimab
COIS- Author SZ and RZ were employed by Shanghai Junshi Biosciences Co., Ltd. The 
      remaining authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/05/03 06:00
MHDA- 2022/05/03 06:01
PMCR- 2022/01/01
CRDT- 2022/05/02 06:27
PHST- 2021/11/16 00:00 [received]
PHST- 2022/03/18 00:00 [accepted]
PHST- 2022/05/02 06:27 [entrez]
PHST- 2022/05/03 06:00 [pubmed]
PHST- 2022/05/03 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.815917 [doi]
PST - epublish
SO  - Front Oncol. 2022 Apr 14;12:815917. doi: 10.3389/fonc.2022.815917. eCollection 
      2022.